button bars forest bayes pooled summary circles
 
Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results

mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive

mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone vs. placebo plus SoC 1 noneinconclusive results for: progression or deaths (PFS); DOR; objective responses (ORR)

suggested 31 % decrease in deaths (OS) but the degree if certainty is unassessable

-
pembrolizumab plus SoC vs. placebo plus SoC 2 noneinconclusive results for: deaths (OS); progression or deaths (PFS); DOR; AE (any grade); AE (grade 3-4); AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); TRAE (any grade); Alopecia TRAE (grade 3-4); Anaemia TRAE (grade 3-4); Asthenia TRAE (grade 3-4); Blood creatinine increased TRAE (grade 3-4); Constipation TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dizziness TRAE (grade 3-4); Dry skin TRAE (grade 3-4); Dysgeusia TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Leucopenia TRAE (grade 3-4); Mucosal inflammation TRAE (grade 3-4); Nausea TRAE (grade 3-4); Neutropenia TRAE (grade 3-4); Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Peripheral sensory neuropathy TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Stomatitis TRAE (grade 3-4); Thrombocytopenia TRAE (grade 3-4); Vomiting TRAE (grade 3-4); Weight decreased TRAE (grade 3-4)

suggested 60 % increase in objective responses (ORR) but the degree if certainty is unassessable

-
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 noneinconclusive results for: deaths (OS); progression or deaths (PFS); DOR; objective responses (ORR); AE (any grade); AE leading to death (grade 5); Alopecia TRAE (grade 3-4); Blood creatinine increased TRAE (grade 3-4); Constipation TRAE (grade 3-4); Dizziness TRAE (grade 3-4); Dry skin TRAE (grade 3-4); Dysgeusia TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Leucopenia TRAE (grade 3-4); Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Thrombocytopenia TRAE (grade 3-4); Weight decreased TRAE (grade 3-4)

suggested 91 % decrease in AE (grade 3-4) but the degree if certainty is unassessable

suggested 81 % decrease in AE leading to treatment discontinuation (any grade) but the degree if certainty is unassessable

suggested 89 % decrease in TRAE (any grade) but the degree if certainty is unassessable

suggested 90 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 91 % decrease in Asthenia TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 84 % decrease in Decreased appetite TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 80 % decrease in Diarrhoea TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 94 % decrease in Fatigue TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 97 % decrease in Mucosal inflammation TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 95 % decrease in Nausea TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 99 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 95 % decrease in Stomatitis TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 97 % decrease in Vomiting TRAE (grade 3-4) but the degree if certainty is unassessable

-

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus paclitaxel
pembrolizumab alone vs. paclitaxel 1 noneinconclusive results for: deaths (OS); progression or deaths (PFS); DOR; objective responses (ORR); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); Alopecia TRAE (grade 3-4); Anaemia TRAE (grade 3-4); Colitis TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diabetes TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypophysitis TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Infusion-related reactions TRAE (grade 3-4); Nausea TRAE (grade 3-4); Pancreatitis TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Severe skin reaction TRAE (grade 3-4)

suggested 79 % decrease in TRAE (any grade) but the degree if certainty is unassessable

suggested 69 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable

suggested 98 % decrease in Neutropenia TRAE (grade 3-4) but the degree if certainty is unassessable

-

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone vs. paclitaxel 1 noneinconclusive results for: deaths (OS); progression or deaths (PFS); DOR; objective responses (ORR)--

mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative

mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons